Latest News about SKYE
Recent news which mentions SKYE
Cannabis Stock Gainers And Losers From August 16, 2023
August 16, 2023
From Benzinga
Cannabis Stock Gainers And Losers From August 14, 2023
August 14, 2023
From Benzinga
Cannabis Stock Gainers And Losers From August 11, 2023
August 11, 2023
From Benzinga
Marijuana Stock Movers For August 8, 2023
August 08, 2023
From Benzinga
From Benzinga
Marijuana Stock Movers For August 2, 2023
August 02, 2023
From Benzinga
Marijuana Stock Movers For August 1, 2023
August 01, 2023
From Benzinga
Marijuana Stock Movers For July 31, 2023
July 31, 2023
From Benzinga
Cannabis Stock Gainers And Losers From July 28, 2023
July 28, 2023
From Benzinga
Cannabis Stock Gainers And Losers From July 26, 2023
July 26, 2023
From Benzinga
Cannabis Stock Movers For July 24, 2023
July 24, 2023
From Benzinga
Cannabis Stock Movers For July 21, 2023
July 21, 2023
From Benzinga
Cannabis Stock Movers For July 20, 2023
July 20, 2023
From Benzinga
Skye Completes Production Of Cannabinoid Based Drug In Preparation For Glaucoma Clinical Trial
July 06, 2023
Tickers
SKYE
From Benzinga
Ethics Committee Approves Starting Multiple Ascending Dose Arm Of Phase 1 Study Of Cannabinoid Based Drug For Treatment Of Glaucoma
March 15, 2023
Tickers
SKYE
From Benzinga
From Benzinga
SOL Global Reduces Principal Amount Of Credit Facility From $50M To $4.52M, Announces Management Changes
February 27, 2023
From Benzinga
Skye Receives Positive Safety Review Of Cannabinoid Based Drug For Treatment Of Glaucoma After Second Cohort Of Phase 1 Study
February 24, 2023
Tickers
SKYE
From Benzinga
Skye One Step Closer To Phase 2 Clinical Trial For Cannabinoid Based Drug For Treatment Of Glaucoma
January 27, 2023
Tickers
SKYE
From Benzinga
Skye Bioscience (OTCQB: SKYE) Heads Into 2023 As A Clinical-Stage Company After Dosing Its First Human Participants
December 22, 2022
From Benzinga
Key Marijuana Executive Changes: Who Will Lead MariMed After CEO's Passing? MJBiz CEO Steps Down
December 19, 2022
From Benzinga
Skye Initiates First-in-Human Phase 1 Clinical Trial For Cannabinoid Based Drug For Treatment Of Glaucoma
November 16, 2022
Tickers
SKYE
From Benzinga
Skye One Step Closer To Initiating Clinical Study Of Its Cannabinoid Based Drug For Treatment Of Glaucoma
September 20, 2022
Tickers
SKYE
From Benzinga
Easy On The Eyes — This Company Reports Using a Unique Synthetic Cannabinoid Derivative To Treat Glaucoma
July 25, 2022
Tickers
SKYE
From Benzinga
Skye Bioscience Signs Arrangement Agreement With Emerald Health Therapeutics, Here Are The Details
May 12, 2022
From Benzinga
Skye Bioscience Shares Up On Keeping Novotech As CRO For Phase 1 Trial Of THC Prodrug Candidate For Glaucoma
March 03, 2022
Tickers
SKYE
From Benzinga
Cannabis Movers & Shakers: Skye Bioscience, The Flowr Corp, Charlotte's Web, Rapid Dose Therapeutics
December 23, 2021
From Benzinga
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.